Literature DB >> 8822463

High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies.

R S Rai1, K Clifford, H Cohen, L Regan.   

Abstract

Antiphospholipid antibodies (APA), lupus anticoagulant (LA) and/or anticardiolipin antibodies (ACA), are associated with thrombosis and recurrent miscarriage. We studied the outcome of 20 pregnancies in women (median age 32 years; range 23-41) with APA (14 LA positive; three immunoglobulin (Ig) G ACA positive; two IgM ACA positive and one LA and IgG ACA positive) and history of recurrent miscarriage (median 4; range 3-11) who declined pharmacological treatment in their next pregnancy. Comparison was made with a cohort of 100 consecutive women (median age 33 years; range 23-44) with recurrent miscarriage (median 4; range 3-10), in whom no underlying cause to account for their pregnancy losses was found. Of the 20 women with APA, 18 (90%) miscarried compared to 34 of the 100 women (34%) with normal investigations (P < 0.001). The majority (94%) of miscarriages in women with APA occurred in the first trimester. Fetal heart activity was seen prior to fetal death in 86% of women with APA compared to 43% of women with normal investigations (P < 0.01). The first trimester loss of embryonic pregnancies is the most common type of miscarriage in women with APA. This may be a result of defective implantation and subsequent placentation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8822463     DOI: 10.1093/oxfordjournals.humrep.a135907

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  24 in total

1.  How to treat women with antiphospholipid antibodies in pregnancy?

Authors:  R H Derksen; P G De Groot; H K Nieuwenhuis; G C Christiaens
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

2.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Intravenous immunoglobulin and recurrent pregnancy loss.

Authors:  Howard J A Carp; Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Autoimmunity: thyroid autoantibodies and pregnancy risk.

Authors:  Erik K Alexander
Journal:  Nat Rev Endocrinol       Date:  2011-07-05       Impact factor: 43.330

5.  Lupus anticoagulants and anticardiolipin antibodies in Indian women with spontaneous, recurrent fetal loss.

Authors:  Akanksha Rawat; Meera Sikka; Usha Rusia; Kiran Guleria
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-08       Impact factor: 0.900

6.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

Review 7.  Anticoagulant therapy and pregnancy.

Authors:  Aiko Makino; Mayumi Sugiura-Ogasawara
Journal:  Reprod Med Biol       Date:  2008-02-01

Review 8.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

9.  Venous thromboembolism in pregnancy.

Authors:  Marcelo P Villa-Forte Gomes
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

Review 10.  Autoimmunity and recurrent pregnancy losses.

Authors:  Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.